Pathophysiology of RAGE in inflammatory diseases
H Dong, Y Zhang, Y Huang, H Deng - Frontiers in Immunology, 2022 - frontiersin.org
The receptor for advanced glycation end products (RAGE) is a non-specific multi-ligand
pattern recognition receptor capable of binding to a range of structurally diverse ligands …
pattern recognition receptor capable of binding to a range of structurally diverse ligands …
CD146, from a melanoma cell adhesion molecule to a signaling receptor
Z Wang, Q Xu, N Zhang, X Du, G Xu… - Signal transduction and …, 2020 - nature.com
CD146 was originally identified as a melanoma cell adhesion molecule (MCAM) and highly
expressed in many tumors and endothelial cells. However, the evidence that CD146 acts as …
expressed in many tumors and endothelial cells. However, the evidence that CD146 acts as …
Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective
S Bongarzone, V Savickas, F Luzi… - Journal of medicinal …, 2017 - ACS Publications
The receptor for advanced glycation endproducts (RAGE) is an ubiquitous, transmembrane,
immunoglobulin-like receptor that exists in multiple isoforms and binds to a diverse range of …
immunoglobulin-like receptor that exists in multiple isoforms and binds to a diverse range of …
Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors
H Singh, DK Agrawal - Drug development research, 2022 - Wiley Online Library
Receptor for advanced glycation end products (RAGE) is a 45 kDa transmembrane receptor
of immunoglobulin family that can bind to various endogenous and exogenous ligands and …
of immunoglobulin family that can bind to various endogenous and exogenous ligands and …
[HTML][HTML] The dual role and therapeutic potential of high-mobility group box 1 in cancer
SJ He, J Cheng, X Feng, Y Yu, L Tian, Q Huang - Oncotarget, 2017 - ncbi.nlm.nih.gov
High-mobility group box 1 (HMGB1) is an abundant protein in most eukaryocytes. It can bind
to several receptors such as advanced glycation end products (RAGE) and Toll-like …
to several receptors such as advanced glycation end products (RAGE) and Toll-like …
S100 proteins as therapeutic targets
AR Bresnick - Biophysical reviews, 2018 - Springer
The human genome codes for 21 S100 protein family members, which exhibit cell-and
tissue-specific expression patterns. Despite sharing a high degree of sequence and …
tissue-specific expression patterns. Despite sharing a high degree of sequence and …
Alarmin S100A11 initiates a chemokine response to the human pathogen Toxoplasma gondii
A Safronova, A Araujo, ET Camanzo, TJ Moon… - Nature …, 2019 - nature.com
Toxoplasma gondii is a common protozoan parasite that infects up to one third of the world's
population. Notably, very little is known about innate immune sensing mechanisms for this …
population. Notably, very little is known about innate immune sensing mechanisms for this …
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker
F Schmid, M Dahlmann, H Röhrich, D Kobelt… - British Journal of …, 2022 - nature.com
Background The metastasis inducing gene MACC1 is a prognostic and predictive biomarker
for metastasis in several cancers. Its mechanism of inducing metastasis includes the …
for metastasis in several cancers. Its mechanism of inducing metastasis includes the …
[HTML][HTML] The life and works of S100P-from conception to cancer
F Prica, T Radon, Y Cheng… - American journal of …, 2016 - ncbi.nlm.nih.gov
Since its discovery in 1992, the small, 10.4 kDa calcium-binding protein S100P has gained
the attention of researchers from different scientific fields due to its potential roles in both …
the attention of researchers from different scientific fields due to its potential roles in both …
[HTML][HTML] The role of S100 proteins and their receptor RAGE in pancreatic cancer
E Leclerc, SW Vetter - Biochimica et Biophysica Acta (BBA)-Molecular Basis …, 2015 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates.
Current therapeutic treatments have very poor response rates due to the high inherent …
Current therapeutic treatments have very poor response rates due to the high inherent …